Relatlimab Clinical Trials
12 recruitingDrug
Phase 210Phase 32Phase 41
Showing 1–12 of 12 trials
Recruiting
Phase 2Phase 3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled493 locationsNCT05987241
Recruiting
Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled299 locationsNCT06561386
Recruiting
Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
Basal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins57 enrolled1 locationNCT03521830
Recruiting
Phase 2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)156 enrolled78 locationsNCT06029270
Recruiting
Phase 4
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
Metastatic MelanomaAdvanced Melanoma
NYU Langone Health90 enrolled1 locationNCT07504796
Recruiting
Phase 2
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Recurrent GlioblastomaProgressive Glioblastoma
National Cancer Institute (NCI)184 enrolled324 locationsNCT06325683
Recruiting
Phase 2
Pan Tumor Rollover Study
Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 2
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma (HNSCC)
Dan Zandberg80 enrolled1 locationNCT04080804
Recruiting
Phase 2
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
Melanoma (Skin)
M.D. Anderson Cancer Center30 enrolled1 locationNCT05704647
Recruiting
Phase 2
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Newly Diagnosed Glioblastoma
Duke University92 enrolled1 locationNCT06816927
Recruiting
Phase 2
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
NeoplasmsNeoplasms by SiteUrinary Bladder Neoplasm+8 more
The Netherlands Cancer Institute90 enrolled9 locationsNCT06237920
Recruiting
Phase 2
Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML
Acute Myeloid Leukemia
Ludwig-Maximilians - University of Munich30 enrolled1 locationNCT04913922